Investment
Features
FeesSafety
Academy
More
Pluang+

Compare 10X Genomics Inc (TXG) vs Union Pacific Corporation (UNP) Price & Performance

10X Genomics IncTrade
Union Pacific CorporationTrade

Price performance (Past 24H)

Key statistics

10X Genomics Inc vs Union Pacific Corporation — how do they compare? 10X Genomics Inc trades at $57.18 (market cap $7.61B), while Union Pacific Corporation trades at $293.89 (market cap $173.99B). The key difference: Union Pacific Corporation is far larger — about 22.9× 10X Genomics Inc's market cap, and Union Pacific Corporation pays a 1.94% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

TXGUNP
Market Cap
$7.61B$173.99B
Sector
HealthIndustrials
52-Week High
$58.57$307.32
52-Week Low
$11.34$214.91
Enterprise Value
$7.14B$203.04B
Dividend Yield
1.94%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Union Pacific Corporation

Union Pacific (UNP) trades at $293.85, up 0.55% with neutral technical signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating estimates at $3.41 versus $3.26 expected, marking the second consecutive quarterly beat. Revenue growth of 12% year-over-year and improved operating efficiency support management's raised full-year EPS guidance. The stock maintains robust profitability metrics including 28.85% net margin and 39.7% ROE, though valuation multiples remain elevated with P/E at 23.71.

Outlook remains positive with analyst consensus price target of $334.33 representing 14% upside potential. Key catalysts include service-led growth driving margin expansion and the pending Norfolk Southern merger offering strategic benefits. Risks include high fuel costs, regulatory scrutiny of the merger, and macroeconomic pressures on freight volumes. Institutional ownership trends show continued accumulation by major funds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG

About Union Pacific Corporation

Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.

Read more on UNP